Peginterferon beta - Toray Industries

Drug Profile

Peginterferon beta - Toray Industries

Alternative Names: PEG-IFN-beta - Toray; PEG-interferon-beta - Toray; Peginterferon-beta - Toray; PEGylated-interferon beta - Toray; TRK-560

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator Toray
  • Class Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Hepatitis C; Multiple sclerosis

Most Recent Events

  • 29 Mar 2016 No recent reports on development identified - Phase-I for Hepatitis C (In volunteers) in Japan (Parenteral)
  • 29 Mar 2016 No recent reports on development identified - Preclinical for Cancer and Multiple sclerosis in Japan (Parenteral)
  • 25 Feb 2009 Phase-I clinical trials in Hepatitis C in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top